| Combigan (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop bid, 12 hours apart |
| Chem Specs | brimonidine tartrate 0.2% / timolol maleate 0.5% |
| Quantities | 5 ml in 10 ml bottle, 10 ml in 10 ml bottle |
| Cost | 239.00/5ml |
| Class | Relatively selective α 2 receptor agonist / beta blocker |
| Action | Brimonidine reduces aqueous production and increases uveoscleral outflow. Timolol reduces aqueous formation by blocking beta2 receptors on nonpigmented ciliary epithelium. Brimonidine reduces aqueous production and increases uveoscleral outflow. Timolol reduces aqueous formation by blocking beta2 receptors on nonpigmented ciliary epithelium. |
| Usage | Adjunctive or replacement therapy for the reduction of IOP. (e.g. commonly replaces prostaglandin for inflammatory glaucomas). |
| About 5% incidence of allergic conjunctivitis (vs 30% with generic brimonidine). 14% discontinuation from all adverse effects. About 5% incidence of allergic conjunctivitis (vs 30% with generic brimonidine). 14% discontinuation from all adverse effects. |
|
| Contraindications | Bronchial asthma, sinus bradycardia, COPD, overt cardiac failure, cardiogenic shock, atrioventricular block and hypersensitivity to any of the product contents. Bronchial asthma, sinus bradycardia, COPD, overt cardiac failure, cardiogenic shock, atrioventricular block and hypersensitivity to any of the product contents. |
| Pediatric use | Contraindicated in children under the age of 2. |
| Pregnancy | Category C. Increased fetal resorptions in mice and rabbits at 83,000 and 8,300 times the normal human dose respectively. Category C. Increased fetal resorptions in mice and rabbits at 83,000 and 8,300 times the normal human dose respectively. |
| 0.005% BAK preserved. 22% average IOP reduction. (May 17, 2024) Glenmark generic FDA approved. Availability to be announced. |